Accessibility Menu
vTv Therapeutics logo

vTv Therapeutics(NASDAQ) VTVT

Market Cap$134.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-92%
5 Year-54%
1 Year+112%
1 Month+10%
Premium Feature
Moneyball Superscore
49/100
$33.89
+1.91%
+0.63Today
vTv Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 33.892026-08-24
vTv Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.24%USD 31.312026-08-17
1 month+10.28%USD 30.732026-07-24
3 month+2.2%USD 33.162026-05-26
Year to date-15.25%USD 39.992025-12-31
1 year+111.81%USD 16.002025-08-22
3 year+67.81%USD 20.202023-08-25
5 year-54.2%USD 74.002021-08-25
Since inception-92.37%USD 435.602015-07-30

vTv Therapeutics Financials at a Glance

Market Cap

$134.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.84M

Net Income (TTM)

-$4.76M

EPS (TTM)

-$1.06

P/E Ratio

-32.04

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$33.89

Volume

17,997.834

Open

$33.42

Previous Close

$33.89

Daily Range

$32.87 - $34.66

52-Week Range

$15.79 - $44.00

Estimated Earnings Date

Nov 5, 2026

VTVT News

No articles available.

VTVT: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About vTv Therapeutics

vTv Therapeutics Inc. makes pills for people with diabetes. These treatments help patients manage chronic diseases without extra injections. The company focuses on making daily health care simpler for everyone.

The Pipeline at a Glance

  • Cadisegliatin: Lead drug candidate currently in a Phase 3 trial as an oral pill for type 1 diabetes.
  • HPP737: Oral inhibitor designed to treat inflammatory conditions like psoriasis without crossing the blood-brain barrier.
  • TTP273: Small-molecule treatment targeting patients who have diabetes related to cystic fibrosis.
  • Other Programs: Research projects focused on kidney disease and conditions caused by oxidative stress.

Strategic Moves and Partnerships

  • Expanded a licensing deal with Newsoara Biopharma in Jan. 2026 to include global rights for the HPP737 program.
  • Partnered with G42 Investments in Dec. 2025 to begin a Phase 2 study for cadisegliatin in the Middle East.
  • Raised $80.0 million in Aug. 2025 through a private placement of stock and warrants to institutional investors.
  • Established a sales agreement in Feb. 2024 to potentially sell up to $50.0 million in stock through TD Cowen.

Helping the Body Sense Sugar

The company uses liver-selective activation to help the body sense glucose like a natural sensor. This method aims to improve blood sugar control while reducing the risk of dangerous drops in sugar levels.

Checking the Ledger

  • Revenue was $36.8 million for the six months ended June 30, 2026, compared to zero in the same period in 2025.
  • Research and development expenses rose 156.0% to $17.7 million during the six months ended June 30, 2026.
  • Net income was $11.1 million for the six months ended June 30, 2026, up from a net loss of $11.1 million in 2025.
  • Cash and cash equivalents totaled $86.6 million as of June 30, 2026.
  • Market capitalization was $90.6 million according to data from Q2 2026.

Bottom Line

vTv Therapeutics has transitioned from early research to late-stage clinical testing of its primary diabetes drug candidate. Its development strategy relies on licensing agreements and milestone payments to fund the move toward commercial oral treatments.

AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

26

CEO

Paul Jai Sekhri

Website

www.vtvtherapeutics.com

Headquarters

High Point, NC 27265, US

VTVT Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-25.11%

Net Income Margin

-12.91%

Return on Equity

-6.27%

Return on Capital

-50.91%

Return on Assets

-5.43%

Earnings Yield

-3.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.95M

Volume

18.00K

Avg. Volume

71.32K

Financials (TTM)

Gross Profit

$36.84M

Operating Income

-$9.25M

EBITDA

-$6.39M

Operating Cash Flow

-$16.76M

Capital Expenditure

$0.00

Free Cash Flow

-$16.76M

Cash & ST Invst.

$86.64M

Total Debt

$0.00

vTv Therapeutics Performance Analysis

vTv Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,018,000-49.6%
20232023-12-31USD 0N/A
20242024-12-31USD 1,017,000N/A
20252025-12-31USD 0N/A
vTv Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30-100.0%
vTv Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.2419.7%
20232023-12-31USD -9.71-5.1%
20242024-12-31USD -3.20-67.1%
20252025-12-31USD -3.200.1%
vTv Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-17.4%
Q42025-12-3121.3%
Q12026-03-31437.6%
Q22026-06-30-136.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$134.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.15M

N/A

Employees

26

N/A

Net Income

-$13.05M

-115.9%

EBITDA

-$13.05M

-76.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$86.64M

+234.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-5.43%

N/A

Return on Invested Capital

-11.48%

N/A

Free Cash Flow

-$11.44M

-124.6%

Operating Cash Flow

-$11.44M

-124.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLKOutlook Therapeutics, Inc.
$0.61-5.90%
SPRBSpruce Biosciences, Inc.
$58.65+13.71%
FBIOFortress Biotech, Inc.
$2.93+2.09%
GANXGain Therapeutics, Inc.
$2.00-0.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$208.48-0.03%
BITOProShares Trust - ProShares Bitcoin ETF
$10.63+0.02%
INTCIntel
$87.26-0.03%
IBITiShares Bitcoin Trust
$44.64+0.02%

Questions About VTVT

What is the current price of vTv Therapeutics?

vTv Therapeutics is trading at $33.89 per share.

What is the 52-week range for vTv Therapeutics?

Over the past 52 weeks, vTv Therapeutics has traded between $15.79 and $44.00.

How much debt does vTv Therapeutics have?

As of the most recent reporting period, vTv Therapeutics reported total debt of $0.00.

How much cash does vTv Therapeutics have on hand?

vTv Therapeutics reported $86.64M in cash and cash equivalents in its most recent financial results.

What is vTv Therapeutics’s dividend yield?

vTv Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services